Document is current
Any future updates will be listed below
-
Authors
Larsen, Arendse Tange
Sopina, Liza https://orcid.org/0000-0002-2680-6999
Mølgaard, Jesper
Aasvang, Eske Kvanner
Meyhoff, Christian S.
Kjellberg, Jakob
Kristensen, Søren Rud
-
Funding
Funding for this research was provided by:
University of Southern Denmark
- License Information
-
More Information
Article History
Received: 27 September 2025
Accepted: 16 March 2026
First Online: 6 April 2026
Declarations
:
: The WARD clinical trial received written approval from the Regional Ethics Committee, Copenhagen, Denmark, February 2018 (H-17033535). All patients gave written informed consent before participating in the study . Register-based research does not require additional or separate ethical approval in Denmark.
: CSM and EKA have founded WARD24/7 ApS, Copenhagen, Denmark, with the aim of pursuing the regulatory and commercial activities of the WARD-project (developing a clinical support system for continuous wireless monitoring of vital signs). WARD24/7 ApS has signed a license agreement for any WARD-project software and patents. One patent has been filed: “Wireless Assessment of Respiratory and circulatory Distress (WARD), EP 21184712.4 and EP 21205557.8” ATL, LS, SRK, JK and JM declare no competing interests.
